Johnson & Johnson: Big Pharma's Q2 2010 Earnings Report

FiercePharma says: Johnson & Johnson met analyst expectations for second-quarter adjusted earnings at $1.21 per share, or $3.45 billion in profits. But its worldwide pharma sales grew by less than 1 percent, and its embattled consumer-drugs segment--which is dealing with manufacturing issues--saw sales fall more than 5 percent to $3.6 billion. J&J cut its profits forecast for the year to $4.65 to $4.75 per share, down from the $4.80 to $4.90 it had predicted in April. The company says part of that decrease stems from currency effects. But it also cited those recalls--and the shutdown of a key consumer-drugs factory, which is keeping a slew of top products such as Tylenol and Motrin off the shelves.

Highlights

  • Sales of $15.3 Billion
  • Increased 0.6% Versus 2009 Second-Quarter
  • EPS was $1.23 Excluding Special Items
  • 2010 Second-Quarter EPS was $1.21, an increase of 5.2%

See J&J's current stock quote from CNN Money

J&J's website: http://www.jnj.com
J&J's full earnings release: J&J release

 

 

Johnson & Johnson: Big Pharma's Q2 2010 Earnings Report
Read more on

Suggested Articles

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.

There's a lot at stake in the world of pharma litigation, and in two cases involving J&J and Gilead, attorney misconduct allegations have come up.

Without any new data, Sarepta appealed an FDA rejection and got a surprising nod for Vyondys 53—its second med approved on a surrogate marker.